[
Bachmanov AA, Bosak NP, Glendinning JI, Inoue M, Li X, Manita S, McCaughey SA, Murata Y, Reed DR, Tordoff MG, Beauchamp GK. Genetics of amino acid taste and appetite. Adv Nutr 7, 806S–822S, 2016.
]Search in Google Scholar
[
Gallagher JA, Dillon JP, Sireau N, Timmis O, Ranganath LR. Alkaptonuria: An example of a “fundamental disease”-A rare disease with important lessons for more common disorders. Semin Cell Dev Biol 52, 53–57, 2016.
]Search in Google Scholar
[
Garrod AE. About Alkaptonuria. Med Chir Trans 85, 69–78, 1902.
]Search in Google Scholar
[
Granadino B, Beltran-Valero de Bernabe D, Fernandez-Canon JM, Penalva MA, Rodriguez de Cordoba S. The human homogentisate 1,2-dioxygenase (HGO) gene. Genomics 43, 115–122, 1997.
]Search in Google Scholar
[
Hughes JH, Wilson PJM, Sutherland H, Judd S, Hughes AT, Milan AM, Jarvis JC, Bou-Gharios G, Ranganath LR, Gallagher JA. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisi-none therapy of alkaptonuria. J Inherit Metab Dis 43, 259–268, 2020.
]Search in Google Scholar
[
Imrich R, Sedlakova J, Ulehlova M, Gornall M, Jackson R, Olsson B, Rudebeck M, Gallagher J, Lukacova O, Mlynarikova V, Stancik R, Vrtikova E, Zanova E, Zatkova A, Arnoux J-B, Rovensky J, Luangrath E, Bygott H, Khedr M, Ranganath LR. Radiological evolution of spinal disease in alkaptonuria and the effect of nitisi-none. RMD Open 8, e002422, 2022.
]Search in Google Scholar
[
Jellum E, Thoresen O, Horn L, Seip R, Nilsen E, Kvittingen EA, Stokke O. Advances in the use of computerized gas chromatography-mass spectrometry and high-performance liquid chromatography with rapid scanning detection for clinical diagnosis. J Chromatogr 468, 43–53, 1989.
]Search in Google Scholar
[
Judd S, Khedr M, Milan AM, Davison AS, Hughes AT, Needham A, Psarelli EE, Shenkin A, Ranganath LR. The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma. JIMD Rep 53, 45–60, 2020.
]Search in Google Scholar
[
Milan AM, Hughes AT, Davison AS, Khedr M, Rovensky J, Psarelli EE, Cox TF, Rhodes NP, Gallagher JA, Ranganath LR. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria. Sci Rep 9, 10024, 2019.
]Search in Google Scholar
[
Millucci L, Bernardini G, Spreafico A, Orlandini M, Braconi D, Laschi M, Geminiani M, Lupetti P, Giorgetti G, Viti C, Frediani B, Marzocchi B, Santucci A. Histological and ultrastructural characterization of alkaptonuric tissues. Calcif Tissue Int 101, 50–64, 2017.
]Search in Google Scholar
[
Nemethova M, Radvanszky J, Kadasi L, Ascher DB, Pires DEV, Blundell TL, Porfirio B, Mannoni A, Santucci A, Milucci L, Sestini S, Biolcati G, Sorge F, Aurizi C, Aquaron R, Alsbou M, Lourenço CM, Ramadevi K, Ranganath LR, Gallagher JA, van Kan C, Hall AK, Olsson B, Sireau N, Ayoob H, Timmis OG, Sang K-HLQ, Genovese F, Imrich R, Rovensky J, Srinivasaraghavan R, Bharadwaj SK, Spiegel R, Zatkova A. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on “black bone disease” in Italy. Eur J Hum Genet 24, 66–72, 2016.
]Search in Google Scholar
[
Olsson B, Ranganath L, Arnoux J-B, Imrich R, Milan A, Rudebeck M. Effects of a protein-restricted diet on body weight and serum tyrosine concentrations in patients with alkaptonuria. JIMD Rep 63, 41–49, 2022.
]Search in Google Scholar
[
Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA. Natural history of alkaptonuria. N Engl J Med 347, 2111–2121, 2002.
]Search in Google Scholar
[
Pollak MR, Chou YH, Cerda JJ, Steinmann B, La Du BN, Seidman JG, Seidman CE. Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat Genet 5, 201–204, 1993.
]Search in Google Scholar
[
Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol 66, 367–373, 2013.
]Search in Google Scholar
[
Ranganath LR, Milan AM, Hughes AT, Dutton JJ, Fitzgerald R, Briggs MC, Bygott H, Psarelli EE, Cox TF, Gallagher JA, Jarvis JC, van Kan C, Hall AK, Laan D, Olsson B, Szamosi J, Rudebeck M, Kullenberg T, Cronlund A, Svensson L, Junestrand C, Ayoob H, Timmis OG, Sireau N, Le Quan Sang KH, Genovese F, Braconi D, Santucci A, Nemethova M, Zatkova A, McCaffrey J, Christensen P, Ross G, Imrich R, Rovensky J. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis 75, 362–367, 2016.
]Search in Google Scholar
[
Ranganath LR, Milan AM, Hughes AT, Khedr M, Davison AS, Shweihdi E, Norman BP, Hughes JH, Bygott H, Luangrath E, Fitzgerald R, Psarelli EE, van Kan C, Laan D, Olsson B, Rudebeck M, Mankowitz L, Sireau N, Arnoux JB, Le Quan Sang KH, Jarvis JC, Genovese F, Braconi D, Santucci A, Zatkova A, Glasova H, Stancik R, Imrich R, Rhodes NP, Gallagher JA. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. J Inherit Metab Dis 43, 737–747, 2020a.
]Search in Google Scholar
[
Ranganath LR, Psarelli EE, Arnoux JB, Braconi D, Briggs M, Broijersen A, Loftus N, Bygott H, Cox TF, Davison AS, Dillon JP, Fisher M, FitzGerald R, Genovese F, Glasova H, Hall AK, Hughes AT, Hughes JH, Imrich R, Jarvis JC, Khedr M, Laan D, Le Quan Sang KH, Luangrath E, Lukacova O, Milan AM, Mistry A, Mlynarikova V, Norman BP, Olsson B, Rhodes NP, Rovensky J, Rudebeck M, Santucci A, Shweihdi E, Scott C, Sedlakova J, Sireau N, Stancik R, Szamosi J, Taylor S, van Kan C, Vinjamuri S, Vrtikova E, Webb C, West E, Zanova E., Zatkova A, Gallagher JA. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol 8, 762–772, 2020b.
]Search in Google Scholar
[
Ranganath LR, Hughes AT, Davison AS, Khedr M, Olsson B, Rudebeck M, Imrich R, Norman BP, Bou-Gharios G, Gallagher JA, Milan AM. Temporal adaptations in the phenylalanine/tyrosine pathway and related factors during nitisinone-induced tyrosinaemia in alkaptonuria. Mol Genet Metab S1096–7192(22)00325–0, 2022a.
]Search in Google Scholar
[
Ranganath LR, Milan AM, Hughes AT, Davison AS, Khedr M, Norman BP, Bou-Gharios G, Gallagher JA, Imrich R, Arnoux JB, Rudebeck M, Olsson B. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria. Sci Rep 12, 16083, 2022b.
]Search in Google Scholar
[
Ranganath LR, Milan AM, Hughes AT, Davison AS, Khedr M, Imrich R, Rudebeck M, Olsson B, Norman BP, Bou-Gharios G, Gallagher JA. Comparing the phenylalanine/tyrosine pathway and related factors between keratopathy and no-keratopathy groups as well as between genders in alkaptonuria during nitisinone treatment. Metabolites 12, 772, 2022c.
]Search in Google Scholar
[
Taylor AM, Hsueh MF, Ranganath LR, Gallagher JA, Dillon JP, Huebner JL, Catterall JB, Kraus VB. Cartilage bio-markers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing. Rheumatology (Oxford) 56, 156–164, 2017.
]Search in Google Scholar
[
Zatkova A, Sedlackova T, Radvansky J, Polakova H, Nemethova M, Aquaron R, Dursun I, Usher JL, Kadasi L. Identification of 11 novel homogentisate 1,2 dioxygenase variants in alkaptonuria patients and establishment of a novel LOVD-based HGD mutation database. JIMD Rep 4, 55–65, 2012.
]Search in Google Scholar
